The microtubule associated protein tau in neurodegenerative diseases. Tauopathies;La proteína tau en enfermedades neurodegenerativas. Taupatías

Revista de Neurologia

Volumn 33, Issue 2, 2001, Pages 169-177

  Sanchez M P ^a   Alvarez Tallada V ^a   Avila J ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Alzheimer disease; Hyperphosphorylation; Microtubule associated protein; Neurofibrillary tangles; Paired helical filaments; Self assembling

Indexed keywords

MICROTUBULE ASSOCIATED PROTEIN; PHOSPHATASE; PHOSPHOTRANSFERASE; TAU PROTEIN;

BINDING AFFINITY; DEGENERATIVE DISEASE; MICROTUBULE; NEUROFIBRILLARY TANGLE; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; REVIEW;

EID: 0034826217     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3302.2001187     Document Type: Review

References (176)

1. Microtubule assembly in vitro. Purification of assembly-promoting factors
2. A protein factor essential for microtubule assembly
3. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin
4. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly
5. Differences in microtubule binding and self-association abilities of bovine brain tau isoforms
6. Amyloid plaques, neurofibrillary tangles and their relevance for the study of Alzheimer's disease
7. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease
8. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain
9. Structure of the bovine tau gene: Alternatively spliced transcripts generate a protein family
10. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains
11. Developmentally regulated expression of specific tau sequences
12. Along the way to a neurofibrillary tangle: A look at the structure of tau
13. The molecular and cellular pathology of Alzheimer neurofibrillary lesions
14. The primary structure and heterogeneity of tau protein from mouse brain
15. Alzheimer disease tangles share immunological similarities with multiphosphorylation repeats in the two large neurofilament proteins
16. Identification of the major multiphosphorylation site in mammalian neurofilaments
17. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2
18. Structure and novel exons of the human tau gene
19. A tau promoter region without neuronal specificity
20. Tau promoter confers neuronal specificity and binds Sp1 and AP-2
21. Primary structure of high molecular weight tau present in the peripheral nervous system
22. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms
23. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system
24. p42 map kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease
25. Immature and mature variants of MAP2 and tau proteins and neuronal plasticity
26. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy
27. Role of glycosaminoglycans in determining the helicity of paired helical filaments
28. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules
29. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly
30. Microtubule bundling by tau proteins in vivo: Analysis of functional domains
31. Pyramidal cell topography of microtubule-associated proteins and their precipitation into paired helical filaments
32. Tau in situ hybridization in normal and Alzheimer brain: Localization in the somatodendritic compartment
33. Tau proteins: The molecular structure and mode of binding on microtubules
34. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif [(306)VQ1VYK(311)] forming beta structure
35. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments
36. Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments
37. Dietary aluminum selectively decreases MAP-2 in brains of developing and adult rats
38. Differential phosphorylation of tau by cyclic AMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase II: Metabolic and functional consequences
39. Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules
40. Microtubule-associated protein tau is phosphorylated by protein kinase C on its tubulin binding domain
41. The pool of MAP kinase associated with microtubules is small but constitutively active
42. Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert-identification of threonine 39 as the primary phosphate acceptor
43. Structural and functional implications of tau hyperphosphorylation: Information from phosphorylation-mimicking mutated tau proteins
44. Downregulation of glycogen synthase kinase-3b (GSK-3b) protein expression during neuroblastoma IMR-32 cell differentiation
45. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments
46. Phosphorylation of tau by proline-directed protein kinase (p34cdc2/p58cyclin A) decreases tau-induced microtubule assembly and antibody SM133 reactivity
47. Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly
48. Phosphorylation of tau by glycogen synthase kinase 3 beta affects the ability of tau to promote microtubule self-assembly
49. Phosphorylation by neuronal cdc2-like protein kinase promotes dimerization of tau protein in vitro
50. Interaction between microtubule-associated protein tau and spectrin
51. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau
52. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies
53. Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau
54. Presenilin 1 associates with glycogen synthase kinase-3 beta and its substrate tau
55. Alpha-synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356
56. Activation of phospholipase C-gamma by the concerted action of tau proteins and arachidonic acid
57. Tau complexes with phospholipase C-gamma in situ
58. Tau interacts with src-family non-receptor tyrosine kinases
59. The naturally occurring PKC inhibitor sphingosine and tumor promoter phorbol ester potentially induce tyrosine phosphorylation/activation of oncogenic proline-directed protein kinase FA/GSK-3alpha in a common signalling pathway
60. The tubulin-binding sequence of brain microtubule-associated proteins, tau and MAP-2, is also involved in actin binding
61. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
62. Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain
63. Tau dephosphorylation at tau-1 site correlates with its association to cell membrane
64. Characterization of microtubule-associated protein phosphoisoforms present in isolated growth cones
65. Identification of nuclear tau isoforms in human neuroblastoma cells
66. A novel tau transcript in cultured human neuroblastoma cells expressing nuclear tau
67. The distribution of tau in the mammalian central nervous system
68. Immunocytochemical localization of tubulin and microtubule-associated protein 2 during the development of hippocampal neurons in culture
69. Tau protein immunoreactivity in dementia of the Alzheimer type: II. Electron microscopy and pathogenetic implications. Effects of fixation on the morphology of the Alzheimer's abnormal filaments
70. Functional organization of microtubule-associated protein tau. Identification of regions which affect microtubule growth, nucleation, and bundle formation in vitro
71. Effects of brain microtubule-associated proteins on microtubule dynamics and the nucleating activity of centrosomes
72. Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau
73. Tau protein function in living cells
74. Purification of tau protein from brain
75. Inhibition of neurite polarity by tau antisense oligonucleotides in primary cerebellar neurons
76. Altered microtubule organization in small-calibre axons of mice lacking tau protein
77. Über eine eigenartige erkrankung der hirnride
78. Alzheimer's disease: Transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn
79. Frequency of stages of Alzheimer-related lesions in different age categories
80. The deposition of amyloid proteins in the aging mammalian brain: Implications for Alzheimer's disease
81. Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease
82. Paired helical filaments in electron microscopy of Alzheimer's disease
83. Mise en évidence immunologique de la protéine tau an niveau des lésions dégénérescence neurofibrillaire de la maladie d'Alzheimer
84. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
85. Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments
86. Alzheimer's paired helical filaments
87. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease
88. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease
89. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau)
90. A modified form of microtubule-associated tau protein is the main component of paired helical filaments
91. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease
92. Structural characterization of the core of the paired helical filament of Alzheimer disease
93. Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease
94. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
95. A neuronal antigen in the brains of Alzheimer patients
96. The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology
97. Conformational change as one of the earliest alterations of tau in Alzheimer's disease
98. Evolution of the neuropathology of Alzheimer's disease
99. Tau aggregation into fibrillar polymers: Taupathies
100. Filamentous nerve cell inclusions in neurodegenerative diseases: Tauopathies and alpha-synucleinopathies
101. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells
102. Disturbance of Notch-1 and Wnt signalling proteins in neuroglial balloon cells and abnormal large neurons in focal cortical dysplasia in human cortex
103. Molecular cloning and characterization of the human glycogen synthase kinase-3 beta promoter
104. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons
105. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons
106. Identification of a tau promoter region mediating tissue-specific-regulated expression in PC12 cells
107. Activation of m(1) muscarinic acetylcholine receptor regulates tau phosphorylation in transfected PC12 cells
108. The phosphorylation of tau: A critical stage in neurodevelopment and neurodegenerative processes
109. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
110. Tau protein becomes long and stiff upon phosphorylation: Correlation between paracrystalline structure and degree of phosphorylation
111. Natural methylamine osmolytes, trimethylamine N-oxide and betaine, increase tau-induced polymerization of microtubules
112. Phosphorylated tau can promote tubulin assembly
113. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins
114. Tau protein in Alzheimer's disease
115. Molecular dissection of the neurofibrillary lesions of Alzheimer's disease
116. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-Dependent protein kinase
117. Molecular dissection of the paired helical filament
118. Inhibition of protein phosphatase-2B (calcineurin) activity towards Alzheimer abnormally phosphorylated tau by neuroleptics
119. Carboxyl methylation of the phosphoprotein phosphatase 2A catalytic subunit promotes its functional association with regulatory subunits in vivo
120. Protein phosphatase 2A: A panoply of enzymes
121. Degradation of tau by lysosomal enzyme cathepsin D: Implication for Alzheimer neurofibrillary degeneration
122. Identification and characterization of the ATP.Mg-dependent protein phosphatase activator (FA) as a microtubule protein kinase in the brain
123. Changes in phosphorylation of tau during ischemia and reperfusion in the rabbit spinal cord
124. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis
125. Modulation of tau phosphorylation and intracellular localization by cellular stress
126. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor
127. Ubiquitin is a component of paired helical filaments in Alzheimer's disease
128. Tau protein and the establishment of an axonal morphology
129. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau
130. Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development
131. The lysosomal system in neurons. Involvement at multiple stages of Alzheimer's disease pathogenesis
132. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus
133. Overexpression of tau protein inhibits kinesin-dependent trafticking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer's disease
134. Self assembly of microtubule associated protein tau into filaments resembling those found in Alzheimer disease
135. Quantitation and characterization of tau factor in porcine tissues
136. In vitro conditions for the self-polymerization of the microtubule-associated protein, tau factor
137. Tau factor polymers are similar to paired helical filaments of Alzheimer's disease
138. The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease
139. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro
140. Deamidation and isoaspartate formation in smeared tan in paired helical filaments. Unusual properties of the microtubule-binding domain of tau
141. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer's disease
142. Polymerization of tau into filaments in the presence of heparin: The minimal sequence required for tau-tau interaction
143. Molecular dissection of the neurofibrillary lesions of Alzheimer's disease
144. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans
145. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments
146. Glycogen synthase kinase 3 phosphorylates recombinant human tau protein at serine-262 in the presence of heparin (or tubulin)
147. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: Differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta
148. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations
149. In vitro polymerization of oxidized tau into filaments
150. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease
151. Oxidative regulation of fatty acid-induced tau polymerization
152. Controlling beta-sheet assembly in genetically engineered silk by enzymatic phosphorylation/dephosphorylation
153. C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease
154. Analysis of microtubule-associated protein tau glycation in paired helical filaments
155. Protein kinase FA/glycogen synthase kinase-3 alpha after heparin potentiation phosphorylates tau on sites abnormally phosphorylated in Alzheimer's disease brain
156. Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal
157. Tau protein pathology in neurodegenerative diseases
158. Oxidative stress in Alzheimer's disease
159. Normal and pathological tau proteins as factors for microtubule assembly
160. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
161. Tau is a candidate gene for chromosome 17 frontotemporal dementia
162. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
163. Frontotemporal dementia and Parkinsonism linked to chromosome 17: A new group of tauopathies
164. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau
165. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly
166. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17
167. Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease
168. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations
169. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform
170. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease
171. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform
172. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice
173. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
174. Tau filament formation in transgenic mice expressing P301L tau
175. Biochemical and molecular characterization of neurofibrillary degeneration in frontotemporal dementias
176. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease